Obesity

Health Elaine Chen

More than 1 billion people have obesity, including 159 million young people, study estimates

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Listen: Legal insider trading, booming biotech stocks, & the next GLP-1

Pharma Elaine Chen

STAT Plus: A ‘vaccine-like’ version of Wegovy is on the drawing board at Novo Nordisk

Biotech Andrew Joseph

STAT Plus: Viking Therapeutics obesity drug hits target in key study, raising hopes for a competitor to existing medicines

Pharma Andrew Joseph

STAT Plus: Obesity treatment from Boehringer Ingelheim, Zealand Pharma succeeds in study in liver condition MASH

Pharma Elaine Chen

STAT Plus: Liver disease MASH is next target for obesity drugs in development

Politics John Wilkerson

STAT Plus: Obamacare plans don’t have to cover weight loss drugs. The government is considering changing that

First Opinion Jody Dushay and Karen S. Greenberg

The complicated connections between weight loss drugs and mental health

Health Simar Bajaj

Opioid cravings were reduced by anti-obesity drug in small study

Health Elaine Chen

STAT Plus: FDA cracks down on websites that claim to sell chemicals in obesity drugs Wegovy, Zepbound

Biotech Allison DeAngelis

STAT Plus: Startup BioAge raises $170 million Series D for Zepbound combination therapy

Biotech Matthew Herper

STAT Plus: Why Eli Lilly’s earnings didn’t quite live up to the hype

Biotech Allison DeAngelis

STAT Plus: Eli Lilly reports tirzepatide MASH success during Q4 earnings

Pharmalot Ed Silverman

STAT Plus: Diabetes treatments have improperly listed patents that should be removed, analysis finds

Matt's Take Matthew Herper

STAT Plus: Novo’s Catalent deal is great for GLP-1s. But what about drug manufacturing?

Pharma Andrew Joseph

STAT Plus: Novo Holdings to purchase drug manufacturer Catalent for $16.5 billion, a deal that could expand Wegovy production

Pharma Elaine Chen

STAT Plus: Wegovy is usually taken indefinitely. Amgen wants a version that can be tapered down

Pharma Andrew Joseph

STAT Plus: As supply crunch starts to ease, Novo Nordisk to offer more doses of obesity drug Wegovy to U.S. patients

Health Elaine Chen

STAT Plus: Can Wegovy treat depression as well as obesity? New research looks to GLP-1 drugs for mental illnesses

First Opinion Jody Dushay

BMI as a barrier to orthopedic surgery doesn’t make sense for patient health

Letters to the editor Torie Bosch

What STAT readers think about JPM’s locked lactation room, covering weight loss drugs, and more

Health Elaine Chen

GLP-1 drugs not linked to suicidal thoughts in FDA’s early review

Health Theresa Gaffney

Nearly 1 in 10 teens globally have used ‘budget Ozempic’ laxatives and other risky weight loss products, per study

Biotech Allison DeAngelis

STAT Plus: Novo Nordisk enlists two Flagship biotechs to develop obesity, MASH drugs

Don't Miss STAT Staff

STAT stories you might have missed in 2023

The Obesity Revolution Elaine Chen, Andrew Joseph, and Damian Garde

STAT Plus: What comes after Wegovy? The quest to eradicate obesity

Pharmalot Ed Silverman

STAT Plus: 3 issues to watch in pharma in 2024

The Obesity Revolution Andrew Joseph

STAT Plus: New weight loss drugs have proven their effectiveness. Now researchers want to know how to best use them

Health Isabella Cueto and Elaine Chen

Obesity drugs’ next tests, and rising threats: 3 chronic disease stories to watch in 2024